Zobrazeno 1 - 10
of 102
pro vyhledávání: '"LCL161"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Arya Afsahi, Christopher M. Silvestri, Allyson E. Moore, Carly F. Graham, Kaylyn Bacchiochi, Martine St-Jean, Christopher L. Baker, Robert G. Korneluk, Shawn T. Beug, Eric C. LaCasse, Jonathan L. Bramson
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundThe genesis of SMAC mimetic drugs is founded on the observation that many cancers amplify IAP proteins to facilitate their survival, and therefore removal of these pathways would re-sensitize the cells towards apoptosis. It has become incre
Externí odkaz:
https://doaj.org/article/eb5ca895b54b482fb6cf4a6da61045ce
Autor:
Sunisa Prasopporn, Orawan Suppramote, Ben Ponvilawan, Chanette Jamyuang, Jantappapa Chanthercrob, Amphun Chaiboonchoe, Pimkanya More-Krong, Kamonchanok Kongsri, Monthira Suntiparpluacha, Rawisak Chanwat, Krittiya Korphaisarn, Seiji Okada, Somponnat Sampattavanich, Siwanon Jirawatnotai
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
Externí odkaz:
https://doaj.org/article/ec0a8457396d49cb9b31dd5bb0eb9d12
Autor:
Sunisa Prasopporn, Orawan Suppramote, Ben Ponvilawan, Chanette Jamyuang, Jantappapa Chanthercrob, Amphun Chaiboonchoe, Pimkanya More-Krong, Kamonchanok Kongsri, Monthira Suntiparpluacha, Rawisak Chanwat, Krittiya Korphaisarn, Seiji Okada, Somponnat Sampattavanich, Siwanon Jirawatnotai
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Cholangiocarcinoma (CCA) is a highly lethal gastrointestinal malignancy that has one of the worst prognoses among solid tumors. The combination of Gemcitabine + Cisplatin (GEM/CIS) remains the standard first-line treatment for advanced stage CCA. How
Externí odkaz:
https://doaj.org/article/911c30605c684512880a37fea8fa7666
Autor:
Kushtrim Kryeziu, Seyed H. Moosavi, Christian H. Bergsland, Marianne G. Guren, Peter W. Eide, Max Z. Totland, Kristoffer Lassen, Andreas Abildgaard, Arild Nesbakken, Anita Sveen, Ragnhild A. Lothe
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-11 (2021)
Abstract Tumor heterogeneity is a primary cause of treatment failure. However, changes in drug sensitivity over time are not well mapped in cancer. Patient-derived organoids (PDOs) may predict clinical drug responses ex vivo and offer an opportunity
Externí odkaz:
https://doaj.org/article/ae8e4589a2914bc0acf2c8d31711cf45
Autor:
Boxiang Zhang, Chengcheng Yang, Rui Wang, Jie Wu, Yunfeng Zhang, Dapeng Liu, Xin Sun, Xiang Li, Hong Ren, Sida Qin
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-17 (2020)
Abstract Background Smac mimetics are a type of drug that can induce apoptosis by antagonizing IAP family members in cancer treatment. However, a recent study showed that Smac mimetics can trigger cell invasion and migration in cancer cells by activa
Externí odkaz:
https://doaj.org/article/db2e92bca7784a6cb2e6660bdf5ffcff
Publikováno v:
Applied Sciences, Vol 11, Iss 1, p 335 (2020)
Inhibitor of apoptosis proteins (IAPs) are suggested as therapeutic targets for cancer treatment. Smac/DIABLO is a natural IAP antagonist in cells; therefore, Smac mimetics have been developed for cancer treatment in the past decade. In this article,
Externí odkaz:
https://doaj.org/article/b8e177fd248849acaa1a2c1ba447d37d
Autor:
Hong Ren, Dapeng Liu, Boxiang Zhang, Xin Sun, Rui Wang, Jie Wu, Xiang Li, Sida Qin, Chengcheng Yang, Yunfeng Zhang
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-17 (2020)
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research : CR
Background Smac mimetics are a type of drug that can induce apoptosis by antagonizing IAP family members in cancer treatment. However, a recent study showed that Smac mimetics can trigger cell invasion and migration in cancer cells by activating the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd940125c6022a520ccdecbccd7ed4a4
http://link.springer.com/article/10.1186/s13046-020-01751-3
http://link.springer.com/article/10.1186/s13046-020-01751-3
Autor:
Marina Konopleva, Nitin Jain, Gautam Borthakur, Carlos E. Bueso-Ramos, Zeev Estrov, Elias Jabbour, Prithviraj Bose, Wei Qiao, Sherry Pierce, Uday R. Popat, Naval Daver, Courtney D. DiNardo, Bing Z. Carter, Maro Ohanian, Lingsha Zhou, Srdan Verstovsek, Sharon D. Bledsoe, Jorge E. Cortes, Po Yee Mak, Xuemei Wang, Guillermo Garcia-Manero, Tapan M. Kadia, Naveen Pemmaraju, Lucia Masarova
Publikováno v:
Blood Adv
Outcomes in patients with high-risk and treatment-resistant myelofibrosis (MF) post-JAK inhibitor therapy remain poor, with no approved drug therapies beyond the JAK inhibitor class. In certain clinical situations, such as severe thrombocytopenia, ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64c452baa6cc529be6f815f772713c42
https://doi.org/10.1182/bloodadvances.2020003829
https://doi.org/10.1182/bloodadvances.2020003829
Publikováno v:
Clinical & Experimental Metastasis. 38:441-449
Osteosarcoma is the most common form of primary bone cancer and frequently metastasizes to the lungs. Current therapies fail to successfully treat over two thirds of patients with metastatic osteosarcoma, so there is an urgent imperative to develop t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::770c3ac4a7ab57cc44b219db17b9bf5a
https://doi.org/10.1007/s10585-021-10116-9
https://doi.org/10.1007/s10585-021-10116-9